Supplementary Figure 13: BCL-xL expression rescues YAP1-depleted cells from growth suppression by RAF-MEK inhibition.
From: The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies

(a,b) Effects of BCL-xL overexpression and YAP1 knockdown on (a) vemurafenib and (b) trametinib sensitivity in HCC364 lung cancer cells (shown are the IC50 and relative cell viability). (c) Immunoblot analysis for each indicated protein in lysates from HCC364 cells overexpressing either GFP or BCL-xL and treated with either control siRNA or YAP1 siRNA.